Good or evil: CD26 and HIV infection.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Good or evil: CD26 and HIV infection.

J Dermatol Sci. 2000 Apr;22(3):152-60. Unique Identifier : AIDSLINE MED/20161978
Ohtsuki T; Tsuda H; Morimoto C; Department of Clinical Immunology and AIDS Research Center, The; Institute of Medical Science, The University of Tokyo, Japan.

Abstract: Acquired immune deficiency syndrome (AIDS) is an incurable disease at present and so many efforts to conquer this disease are being made around the world. In studies of human immunodeficiency virus (HIV) infection and the disease progression, it has been reported that T cells expressing CD26 are preferentially infected and depleted in HIV-infected individuals. CD26 is a widely distributed 110 kDa cell-surface glycoprotein with known dipeptidyl peptidase IV (DPPIV) activity in its extracellular domain. This ectoenzyme is capable of cleaving N-terminal dipeptides from polypeptides with either proline or alanine residues in the penultimate position. On human T cells, CD26 exhibits the co-stimulatory function and plays an important role in immune response via its ability to bind adenosine deaminase (ADA) and association with CD45. Recent studies have been stripping the veil from over the relationship between CD26 and HIV infection. Susceptibility of cells to HIV infection is correlated with CD26 expression, and HIV transactivator Tat and envelope protein gp120 are reported to interact with CD26. These observations indicate that CD26 is closely involved in HIV cell entry and that CD26-mediated T cell immune response is suppressed. In addition, it has been demonstrated that the anti-HIV and chemotactic activities of RANTES (regulated on activation, normal T cell expressed and secreted) and stromal cell-derived factor-1 (SDF-1) are controlled with the DPPIV activity of CD26. Thus, the regulation of the function of chemokines by CD26/DPPIV appears to be essential for lymphocyte trafficking and infectivity of HIV strains.

Keywords: JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL Amino Acid Sequence Antigens, CD26/*METABOLISM Binding Sites/GENETICS Chemokines/GENETICS/METABOLISM Chemokines, CXC/GENETICS/METABOLISM CD4 Lymphocyte Count Gene Products, tat/METABOLISM Human HIV Infections/ENZYMOLOGY/ETIOLOGY/*IMMUNOLOGY Models, Biological Molecular Sequence Data RANTES/GENETICS/METABOLISM Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. T-Lymphocytes/ENZYMOLOGY/IMMUNOLOGY

000630
A0062000

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .